Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON51740
NL-OMON51740
Recruiting
Not Applicable

POINTING: Towards patient-tailored cancer immunotherapy supported by a multifaceted predictive signature composed of integrative omics and molecular imaging. - POINTING

niversitair Medisch Centrum Groningen0 sites200 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsNSCLCskin cancer (melanoma)10027476

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
NSCLC
Sponsor
niversitair Medisch Centrum Groningen
Enrollment
200
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Histologically or cytological documented locally advanced or metastatic
  • •NSCLC or melanoma.
  • •2\. Patients must be eligible for standard treatment with immune checkpoint
  • •inhibitor antibody treatment (monotherapy or in combination with other
  • •anti\-cancer treatments).
  • •3\. Age \>\=18 years.
  • •4\. Measurable disease, as defined by standard RECIST v1\.1\. Previously
  • •irradiated lesions should not be counted as target lesions.
  • •5\. Metastatic or locally advanced lesion(s) of which a histological biopsy can
  • •safely be obtained according to standard clinical care procedures

Exclusion Criteria

  • •1\. Malignancies other than melanoma or NSCLC within 5 years prior to inclusion,
  • •with the exception of those with a negligible risk of metastasis or death,
  • •treated with expected curative outcome (such as adequately treated carcinoma in
  • •situ of the cervix, basal or squamous cell skin cancer, localized prostate
  • •cancer treated with curative intent or ductal carcinoma in situ treated
  • •surgically with curative intent).
  • •2\. Treatment with systemic immunosuppressive medications (including but not
  • •limited to prednisone, cyclophosphamide, azathioprine, methotrexate,
  • •thalidomide, and anti\-tumor necrosis factor agents) within 2 weeks prior to
  • •study inclusion.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Towards patient tailored cancer treatment supported by molecular imaging IMPACT: IMaging PAtients for Cancer drug selecTion - Metastatic Breast Cancermammacarcinomametastatic breast cancer10006291
NL-OMON41527niversitair Medisch Centrum Groningen200
Active, not recruiting
Not Applicable
Imaging patients for cancer drug selection - metastatic breast cancerMetastatic Breast CancerTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-000551-41-NLniversity Medical Center Groningen
Recruiting
Not Applicable
Development of Novel Immunotherapy for Canceriquid and Solid Tumors
JPRN-UMIN000052314Ehime University Graduate School of Medicine20
Recruiting
Not Applicable
Target to B! - Towards patient-tailored immunotherapy to effectively treat B-cell associated diseasehematologische aandoeningenB-cell related disordersB-cell mediated immunological or oncological disorders10003816
NL-OMON49992Academisch Medisch Centrum2,000
Recruiting
Phase 1
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudySolid tumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
CTIS2023-507418-28-00F. Hoffmann-La Roche AG825